Our data indicate that CAPE treatment decreases BFT-induced IL-8 (the human equivalent of CXCL1) expression by inhibiting NF-κB in intestinal epithelial cells, resulting in reduced inflammation in the large intestine during colitis and CRC. Here, CXCL1 is linked to colitis.